AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04643314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided video-based self-evaluation
Description: In addition to their usual residency training, participants randomized to this group will undergo the following interventions:~The participants will be asked to review their own operating room recordings (of each of the 5 consecutive submitted laparoscopic cholecystectomy cases that the participant acted as the primary operator) and to assess themselves (within 72 hours (3 days) of the procedure) using validated intra-operative assessment tools. The completion of the self-evaluations is to guide and document video-based self-reflection. The duration of self-assessment/reflection session will be up do the participant. Residents in this group will have unlimited access to their recordings through the web-based platform. On the other hand, they will not be able to access the battery of assessment forms after the third day following the procedure.
Study NCT02322229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin 0.125 mg in a 0.1 mL volume
Study NCT00609843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipiodol demarcation of the bladder tumour
Description: 1-3 drops of Lipiodol Ultra Fluid (iodine 38%W/W) will be injected into the submucosa on 4 locations around the bladder tumour. The procedure is done once during a planned cystoscopy approximately a week before the planning CT.
Study NCT00581685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin, Celecoxib
Description: Pregabalin (75mg BID) and Celecoxib(100mg BID) two weeks prior to hip arthroplasty and 3 weeks postoperatively.
Study NCT04382196 — intervention group
Intervention type: OTHER
Intervention: Online survey
Description: An online survey will be administered
Study NCT02345304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study NCT02345304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study NCT02345304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181
Study NCT02345304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT02345304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study NCT04243603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK)
Description: Please see description of experimental arm (arm one)
Study NCT04243603 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK)
Description: Please see description of experimental arm (arm one)
Study NCT02495350 — intervention group
Intervention type: OTHER
Intervention: Questionarie
Description: Parturients will be asked to fill out a labor satisfaction questionnaire detailing initial desire for epidural analgesia, final desire for epidural analgesia, adequacy of pain relief during labor and satisfaction with laborOn the third day postoperatively the parturients will be called and assessed for mood and signs of postpartum depression using Edinborough Postnatal Depression scale validated into Hebrew (10) , and we will assess whether or not they are breastfeeding.~At 6 weeks we will follow-up to assess breastfeeding duration ,and postpartum depression using the Edinborough Postnatal Depression scale.~Our comparison will include average pain scores, breast feeding success, and postpartum depression assessment.
Study NCT00932425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardionet Mobile Cardiac Outpatient Telemetry (MCOT)
Description: Patients will be assigned to wear the telemetry device for 21 days
Study NCT02320955 — intervention group
Intervention type: PROCEDURE
Intervention: Reimplantation of cryoconserved bone flap
Description: A bone flap, which was explanted for decompression of a swollen brain or following severe head trauma and which was cryoconserved in the meantime is reimplanted. This procedure is the gold-standard therapy after decompressive hemicraniectomy and is routinely performed.
Study NCT03982342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cather closure of patent ductus arteriosus (PDA)
Description: Infants assigned to this group will have a catheter run from a blood vessel in the upper leg / groin area to the heart, where an FDA-approved device will be placed within the patent ductus arteriosus to occlude or plug it, thereby closing the ductus.
Study NCT03982342 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative management of patent ductus arteriosus (PDA)
Description: Infants with a hemodynamically-significant patent ductus arteriosus randomized to this group will be treated by fluid restriction and possible diuretic use to reduce PDA symptoms, and allow time to permit the PDA to close or become reduced in size to the point where it is no longer considered hemodynamically-significant.
Study NCT00526981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone position
Description: Prone position during spontaneous breathing.
Study NCT03571763 — intervention group
Intervention type: OTHER
Intervention: SWI sequence
Description: Acute ischemic stroke patient confirmed by SWI sequence
Study NCT03517384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-CBT for Body Dysmorphic Disorder
Description: The current intervention, is a therapist guided, Internet Cognitive Behavioral Therapy treatment for Body Dysmporhic Disorder which consists of 8 treatment modules administered over the course of 12 weeks.
Study NCT00403754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).
Study NCT00403754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study NCT00403754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.
Study NCT01669967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 5 mg/kg in 250 ml of normal saline infused over 45 minutes.
Study NCT01669967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg in 250 ml of normal saline infused over 45 minutes.
Study NCT02803853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intervention components will occur at the policy level (working with tribal leaders makers to sustain intervention components; food retail outlet level (working with grocery stores and owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with worksites and schools to deliver nutrition intervention sessions to youth and adults in intervention neighborhoods); household level (providing a social media program that provides parents and caregivers tips for healthier eating).
Study NCT02823249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1.56 g L-Tryptophan
Study NCT02823249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1.56 g L-Leucine
Study NCT02823249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 50 g Xylitol
Study NCT02823249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 75 g Erythritol
Study NCT02823249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 75 g Glucose
Study NCT02823249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tap water
Study NCT02823249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tap water
Study NCT02823249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)
Study NCT02823249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)
Study NCT02823249 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube
Study NCT02823249 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasogastric Tube
Study NCT02979925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcutaneous Magnetic Stimulation
Description: Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
Study NCT02979925 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Magnetic Stimulation
Description: Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
Study NCT02041754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IQP-AK-102
Study NCT02041754 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04160351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400
Description: medium cut-off dialyser
Study NCT04160351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elisio-19H
Description: high flux dialyser
Study NCT04343248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide 600 mg administered orally twice daily for six weeks
Study NCT04343248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally twice daily for six weeks
Study NCT04343248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin Super B-Complex
Description: Vitamin Super B-Complex administered orally twice daily to maintain the blind
Study NCT04343248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Super B-Complex
Description: Vitamin Super B-Complex administered orally twice daily to maintain the blind
Study NCT02708095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT02708095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01320982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline
Description: minocycline 100 mg/bid
Study NCT01320982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole
Description: pramipexole 0.125, 0.25, 0.5 and 0.75 mg/bid
Study NCT01320982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: acetylsalicylic acid 500mg/ bid
Study NCT01320982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo bid
Study NCT03530072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Karius Test
Description: Next Generation Sequencing
Study NCT02930824 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotyping
Description: All proton pump inhibitors are metabolized in part by the CYP2C19 enzyme, which is encoded by the highly polymorphic CYP2C19 gene. Based on variations within this gene the effectiveness of the drug may be reduced.
Study NCT02556840 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: insulin therapy
Study NCT02556840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: insulin therapy
Study NCT02540629 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bundled EMS CPR approach including dispatcher-assisted CPR, 3-person team CPR, and feedback CPR monitoring device
Description: Gold standard EMS CPR refers to our bundled approach to providing high quality EMS CPR through one or more intervention(s) as applicable including 1) dispatcher-assisted CPR, 2) multi-tiered team CPR, and 3) feedback CPR.
Study NCT02368834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: The intervention included a presentation by a psychiatrist, with parent manual provided, and then two group sessions at the 2nd and 4th weeks to address further concerns of the parents
Study NCT00354432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oral soy protein/isoflavones powder
Description: Soy protein powder (20gm) orally 160 mg of total isoflavones isocaloric supplement of casein protein
Study NCT00354432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oral soy protein/isoflavones powder
Description: Soy protein powder (20gm) orally 160 mg of total isoflavones isocaloric supplement of casein protein
Study NCT00354432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Patients receive oral venlafaxine 75mg.
Study NCT00354432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Venlafaxine
Description: Patients receive oral venlafaxine 75mg.
Study NCT00354432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Powder
Description: Placebo powder (20gm casein protein) orally 0 mg of total isoflavones
Study NCT00354432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Powder
Description: Placebo powder (20gm casein protein) orally 0 mg of total isoflavones
Study NCT00354432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Pill
Description: Patients receive oral placebo pill.
Study NCT02435342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalazatide
Description: Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.
Study NCT02435342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, Subcutaneous injection twice per week for a total of 9 doses
Study NCT00493220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC HYLENEX and Ceftriaxone
Description: single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
Study NCT00493220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Placebo and Ceftriaxone
Description: single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
Study NCT00493220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ceftriaxone
Description: single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)
Study NCT01889238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg administered as four soft gelatin capsules orally once daily
Study NCT03769766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Take medication one 500 mg pill of BCM-95 taken twice daily
Study NCT03769766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take medication one 500mg pill twice daily
Study NCT03369223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986249
Description: Specified dose on specified days
Study NCT03369223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03369223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT02905422 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: H.E.A.L.T.H. II Intervention
Description: 12 month study with 6 month intervention phase and 6 month follow up phase. Participants will receive bi-weekly educational information pertaining to weight loss during the intervention phase. Participants will use online website to monitor weight, access meal plans, access weight loss information, and access fitness plans.
Study NCT02473042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: Electrical stimulation to the wrist initiated at 1mHz, 1 pulse/second using two leads on a nerve stimulator. Stimulation continued throughout the breast surgery.
Study NCT02473042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran
Description: 4 mg by vein for 1 dose.
Study NCT02473042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: 4 mg by vein for 1 dose.
Study NCT02473042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg by vein for 1 dose.
Study NCT02473042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 10 mg by vein for 1 dose.
Study NCT02473042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenergan
Description: 6.25 mg by vein for 1 dose.
Study NCT02473042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenergan
Description: 6.25 mg by vein for 1 dose.
Study NCT02473042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pepcid
Description: 10 mg by vein for 1 dose.
Study NCT02473042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pepcid
Description: 10 mg by vein for 1 dose.
Study NCT02473042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.
Study NCT02473042 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.
Study NCT00785785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib (AMN107)
Study NCT00785785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib (STI571)
Study NCT03498937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: 10 active tDCS sessions (2 sessions/day for 5 days, 30 min each, 2 mA) applied to the dlPFC
Study NCT03226704 — intervention group
Intervention type: PROCEDURE
Intervention: Leukapheresis
Description: Leukapheresis
Study NCT04280276 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TruGraf test
Description: To obtain longitudinal TruGraf testing in patients with stable creatinine, high and normal IPV in tacrolimus levels, between 3 and 18 months post-transplant at the University of Maryland post-transplant clinic.
Study NCT02964858 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Arm
Description: Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT , CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
Study NCT02964858 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental Arm
Description: Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT,CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
Study NCT03498937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: 10 sham tDCS sessions (2 sessions/day for 5 days, 30 min each, 0 mA) applied to the dlPFC
Study NCT02763501 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closure of mesenteric defects
Description: Closure of mesenteric defects by use of non-absorbable running sutures in RCT; and according to the choice of the surgeon in the non-RCT
Study NCT02763501 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-closure of mesenteric defects
Description: Mesenteric defects are left open